Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors

• DOI: 10.3346/jkms.2017.32.7.1124
• Publication Date: 2017-06-05T10:57:05Z
• Authors: Ji-Ho Lee; Su-Chin Kim; Hyunna Choi; Chang-Gyu Jung; Ga-Young Ban; Yoo Seob Shin; Dong-Ho Nahm; Hae-Sim Park; Young-Min Ye
• Keywords: Allergen Immunotherapy; Aeroallergen

Allergen-specific immunotherapy is the only causal treatment for allergic diseases.However, efficacy of may vary around world due to differences in climate, nature aero-allergens and their distribution.The aim this study was describe effects subcutaneous (SCIT) Korean adults with asthma (AA).As a retrospective cohort study, we reviewed medical records 627 patients AA Korea who were sensitized house dust mite (HDM) and/or pollens underwent SCIT aluminum hydroxide adsorbed allergen extract from 2000 2012.Rates remission, defined as no further requirement maintenance medication, over time determined by means life tables extension survival analysis.Herein, asthmatic achieved remission within mean 4.7 ± 0.2 years.The cumulative incidence rates 86.9% upon SCIT.Baseline forced expiratory volume first second (FEV1) ≥ 80% (hazard ratio [HR], 3.10; 95% confidence interval [CI], 1.79-5.39;P < 0.001), more than 3 years (HR, 1.82; CI, 1.21-2.72;P = 0.004) significant predictors during SCIT.In 284 on HDM alone, initial specific immunoglobulin E (IgE) levels Dermatophagoides pteronyssinus farinae did not show difference between non-remission group after adjusting demographic variables.In conclusion, effective safe modality AA.Initial FEV1 found be associated favorable clinical responses SCIT.